Ticarcillin plus amikacin is a standard therapy for the treatment of infected granulocytopenic cancer patients. It has been compared with other antibiotic combinations for the empiric therapy of suspected sepsis in this patient group and has withstood the test of time (2, 10). However, because aminoglycoside therapy has been associated with high rates of both nephro-and ototoxicity, a single, relatively nontoxic agent would be preferred (1; W. Pickard, D. Durack, and H. Gallis, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 22nd, Miami Beach, Fla., abstr. no. 5, 1982) .
Ceftazidime is a new aminothiazolyl cephalosporin with a microbiological spectrum that encompasses Staphylococcus aureus plus members of the family Enterobacteriaceae. This compound also has been found to be highly microbiologically active against Pseudomonas aeruginosa (9), a major addition over currently available expanded-spectrum cephalosporins. Consequently, we decided to evaluate ceftazidime in comparison with ticarcillin plus amikacin with regard to the serum bactericidal activity produced in volunteers against P. aeruginosa, Escherichia coli, Klebsiella pneumoniae, and S. aureus, the most common pathogens recovered from the blood of granulocytopenic cancer patients.
MATERIALS AND METHODS
Volunteer studies. Normal male volunteers (age, 18 to 35 years; weight, 59 to 86.4 kg), fully informed before the study, received both ceftazidime and the combination of ticarcillin plus amikacin in a crossover manner, with at least 6 days elapsing between each administration. Ceftazidime (2 g) or ticarcillin (5 g) plus amikacin (7.5 mg/kg) were each diluted to 23 ml with 5% glucose in water and infused via a Harvard pump (Harvard Apparatus, Inc.) for 30 min. When ticarcillin plus amikacin was administered, the aminoglycoside was always infused first. Blood was obtained for serum bactericidal assay 1 and 6 h after the termination of the infusions.
Microbiological methods. A total of 31 strains of P. aeruginosa and 7 strains each of E. coli, K. pneumoniae, and S. * Corresponding author.
aureus were chosen at random from a collection derived from the clinical services of the University of Maryland Cancer Center. The MICs of the test antimicrobial agents were determined concurrently for each organism. The determinations were performed by a microtiter dilution method, using Mueller-Hinton broth supplemented with calcium and magnesium as the growth medium and diluent. An overnight broth culture was adjusted to visually equal the density of a 0.5 McFarland standard (_ 108 CFU/ml). A further 1:200 dilution was made of this adjusted culture. The test wells contained 0.05 ml of antibiotic plus 0.05 ml of this dilution, producing an inoculum of ca. 105 to 106 CFU/ml. The MIC was defined as the lowest concentration that prevented grossly detectable growth after 18 h of incubation at 37°C.
Serum bactericidal activity. The bactericidal activity of serum samples was determined by a microtiter dilution method, utilizing equal quantities of pooled human serum and cation-supplemented Mueller-Hinton broth as the diluent (7) . All samples were serially diluted from 1:2 to 1:256.
The inoculum was 105 to 106 bacteria per ml. The endpoint for the serum inhibitory activity was the last well in which there was no turbidity. The endpoint for the serum bactericidal activity was determined as the greatest dilution which allowed no growth after subculturing 0.0015 ml of each nonturbid well onto agar plates (ca. 99.9% kill).
Statistical analysis. The geometric mean serum bactericidal activity calculated for each species of microorganism was tested by Student's t test to determine significant differences. The cumulative percentage of the serum bactericidal activity at each level of dilution was calculated for each species of microorganism for each drug.
RESULTS
Microbiological activity. The MICs of the test antimicrobial agents for inhibition of the organisms are displayed in Table 1 . Ceftazidime was clearly the most active single agent against P. aeruginosa, with 30 of 31 strains susceptible to 8 ,ug/ml. Amikacin was also highly active, with 27 of 31 strains susceptible to 8 ,ug/ml. Ticarcillin displayed a different order 16 ,ug/ml. Serum bactericidal activity. The geometric mean serum bactericldal titers for both regimens at both 1 and 6 h are displayed in Table 2 . The geometric mean bactericidal titers of ceftazidime were significantly better than those obtained with ticarcillin plus amikacin at both 1 and 6 h for each species of gram-negative bacilli. Against the 31 strains of P. aeruginosa, ceftazidime produced a geometric mean bactericidal titer of 1:40.7 after 1 h of antibiotic administration, which was over three times that generated by the combination of ticarcillin plus amikacin (1:12.2). At 6 h, the bactericidal titer of ceftazidime was still greater than twice that generated by the combination. Against E. coli and K. pneumoniae, ceftazidime showed uniformly good serum bactericidal activity at both 1 and 6 h, the lowest mean titer being 1 Against E. coli and K. pneumoniae, both regimens performed extremely well with ticarcillin plus amikacin, generating higher bactericidal titers against K. pneumoniae than would be expected on the basis of the microbiological activity of the agents involved. This is probably due to a synergistic interaction between the beta-lactam and the aminoglycoside for this organism. adequate until the organism is identified and more specific therapy can be initiated cannot be answered from the available information and will have to be addressed in clinical trials. The antistaphylococcal activity seen with the combination of ticarcillin plus amikacin is somewhat greater than would be expected. Although this activity may be influenced by inoculum size, it is important to note that clinical trial experience has shown that ticarcillin plus an aminoglycoside provides very effective antimicrobial therapy in the empiric treatment situation for the staphylococcus (3).
In summary, ceftazidime is a new aminothiazolyl cephalosporin which appears to be a very active single agent for P. aeruginosa. It couples this antipseudomonal activity with excellent killing power against members of the family Enterobacteriaceae. Against S. aureus, however, the activity of ceftazidime is somewhat more suspect, and the serum bactericidal activity achieved is of an order which raises doubts as to its protective ability for neutropenic cancer patients in the empiric therapy situation. The prediction of efficacy for gram-negative infections and the question of adequacy of ceftazidime for staphylococcal infections clearly need resolution in well-controlled, comparative clinical trials.
